Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin

Morio Nakamura, Naoki Hasegawa, Naoki Miyao, Takahiro Nakajima, Takeshi Terashima, Fumio Sakamaki, Rika Hiraoka, Hiroaki Matsubara, Yoshitaka Oyamada, Makoto Yonemaru, Kazumi Nishio, Naoto Shimada, Ichiro Kawada, Katsuhiko Naoki, Sadatomo Tasaka, Tomoyasu Nishimura, Akitoshi Ishizaka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

[Objective]: This study was conducted in patients of secondary infection with chronic respiratory disease in order to compare 5 day short-course therapies employing gatifloxacin(GFLX) and levofloxacin(LVFX). In addition to the shortening of treatment periods, we also investigated the economic efficiency of this medical treatment. [Materials and methods]: A total of 74 patients with secondary infection in chronic respiratory disease were enrolled and treated with the study drugs. The study was conducted between September, 2006 and April, 2007 at Keio University Hospital and its affiliated hospitals and clinics. This was a randomized study in which patients were randomly assigned to one of the following two treatment groups: GFLX group (200 mg twice daily for patients aged ≧ 65 years and 400 mg twice daily in patients aged < 65 years), LVFX group (400 mg twice daily). The duration of antibiotic therapy was 5 days. [Results]: 61 patients (GFLX group: 32, LVFX group: 29) were evaluated for the efficacy of the medications, 74 patients (GFLX group: 37, LVFX group: 37) were evaluated for side effects, and 63 patients (GFLX group: 30, LVFX group: 33) were evaluated for abnormal laboratory results from a total of 74 patients. Clinical efficacy was 90.6% (29/32) in the GFLX group and 89.7% (26/29) in the LVFX group. Side effects were observed in 2 cases in the GFLX group, and 2 abnormal laboratory results were observed (1 in the GFLX group and 1 in the LVFX group). These cases were all mild in nature. [Conclusion]: Conventional management recommends 7-14 days of antibiotic therapy for secondary infection in patients with chronic respiratory disease. However, the optimum duration of treatment is less clear. This study suggests that for secondary infection in chronic respiratory disease, 5 day short-course therapy employing antibiotics therapy can be clinically successful. In terms of the economic efficiency of this medical treatment, GFLX is superior to LVFX due to the lower cost of this drug. These results show that therapy involving a 5 day short-course using GFLX is of greater benefit than therapy involving the use of LVFX.

Original languageEnglish
Pages (from-to)451-462
Number of pages12
JournalJapanese Journal of Chemotherapy
Volume55
Issue number6
Publication statusPublished - 2007 Nov

Fingerprint

Levofloxacin
Coinfection
Chronic Disease
Therapeutics
Medical Economics
Anti-Bacterial Agents
gatifloxacin
Drug Costs

Keywords

  • 5-day therapy
  • Chronic respiratory disease
  • Gatifloxacin
  • Levofloxacin
  • Secondary infection

ASJC Scopus subject areas

  • Pharmacology

Cite this

Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin. / Nakamura, Morio; Hasegawa, Naoki; Miyao, Naoki; Nakajima, Takahiro; Terashima, Takeshi; Sakamaki, Fumio; Hiraoka, Rika; Matsubara, Hiroaki; Oyamada, Yoshitaka; Yonemaru, Makoto; Nishio, Kazumi; Shimada, Naoto; Kawada, Ichiro; Naoki, Katsuhiko; Tasaka, Sadatomo; Nishimura, Tomoyasu; Ishizaka, Akitoshi.

In: Japanese Journal of Chemotherapy, Vol. 55, No. 6, 11.2007, p. 451-462.

Research output: Contribution to journalArticle

Nakamura, M, Hasegawa, N, Miyao, N, Nakajima, T, Terashima, T, Sakamaki, F, Hiraoka, R, Matsubara, H, Oyamada, Y, Yonemaru, M, Nishio, K, Shimada, N, Kawada, I, Naoki, K, Tasaka, S, Nishimura, T & Ishizaka, A 2007, 'Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin', Japanese Journal of Chemotherapy, vol. 55, no. 6, pp. 451-462.
Nakamura, Morio ; Hasegawa, Naoki ; Miyao, Naoki ; Nakajima, Takahiro ; Terashima, Takeshi ; Sakamaki, Fumio ; Hiraoka, Rika ; Matsubara, Hiroaki ; Oyamada, Yoshitaka ; Yonemaru, Makoto ; Nishio, Kazumi ; Shimada, Naoto ; Kawada, Ichiro ; Naoki, Katsuhiko ; Tasaka, Sadatomo ; Nishimura, Tomoyasu ; Ishizaka, Akitoshi. / Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin. In: Japanese Journal of Chemotherapy. 2007 ; Vol. 55, No. 6. pp. 451-462.
@article{fc93ed7682c744f08764beb25825de21,
title = "Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin",
abstract = "[Objective]: This study was conducted in patients of secondary infection with chronic respiratory disease in order to compare 5 day short-course therapies employing gatifloxacin(GFLX) and levofloxacin(LVFX). In addition to the shortening of treatment periods, we also investigated the economic efficiency of this medical treatment. [Materials and methods]: A total of 74 patients with secondary infection in chronic respiratory disease were enrolled and treated with the study drugs. The study was conducted between September, 2006 and April, 2007 at Keio University Hospital and its affiliated hospitals and clinics. This was a randomized study in which patients were randomly assigned to one of the following two treatment groups: GFLX group (200 mg twice daily for patients aged ≧ 65 years and 400 mg twice daily in patients aged < 65 years), LVFX group (400 mg twice daily). The duration of antibiotic therapy was 5 days. [Results]: 61 patients (GFLX group: 32, LVFX group: 29) were evaluated for the efficacy of the medications, 74 patients (GFLX group: 37, LVFX group: 37) were evaluated for side effects, and 63 patients (GFLX group: 30, LVFX group: 33) were evaluated for abnormal laboratory results from a total of 74 patients. Clinical efficacy was 90.6{\%} (29/32) in the GFLX group and 89.7{\%} (26/29) in the LVFX group. Side effects were observed in 2 cases in the GFLX group, and 2 abnormal laboratory results were observed (1 in the GFLX group and 1 in the LVFX group). These cases were all mild in nature. [Conclusion]: Conventional management recommends 7-14 days of antibiotic therapy for secondary infection in patients with chronic respiratory disease. However, the optimum duration of treatment is less clear. This study suggests that for secondary infection in chronic respiratory disease, 5 day short-course therapy employing antibiotics therapy can be clinically successful. In terms of the economic efficiency of this medical treatment, GFLX is superior to LVFX due to the lower cost of this drug. These results show that therapy involving a 5 day short-course using GFLX is of greater benefit than therapy involving the use of LVFX.",
keywords = "5-day therapy, Chronic respiratory disease, Gatifloxacin, Levofloxacin, Secondary infection",
author = "Morio Nakamura and Naoki Hasegawa and Naoki Miyao and Takahiro Nakajima and Takeshi Terashima and Fumio Sakamaki and Rika Hiraoka and Hiroaki Matsubara and Yoshitaka Oyamada and Makoto Yonemaru and Kazumi Nishio and Naoto Shimada and Ichiro Kawada and Katsuhiko Naoki and Sadatomo Tasaka and Tomoyasu Nishimura and Akitoshi Ishizaka",
year = "2007",
month = "11",
language = "English",
volume = "55",
pages = "451--462",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "6",

}

TY - JOUR

T1 - Comparison of 5 day short-course therapies for secondary infection in patients with chronic respiratory disease using gatifloxacin and levofloxacin

AU - Nakamura, Morio

AU - Hasegawa, Naoki

AU - Miyao, Naoki

AU - Nakajima, Takahiro

AU - Terashima, Takeshi

AU - Sakamaki, Fumio

AU - Hiraoka, Rika

AU - Matsubara, Hiroaki

AU - Oyamada, Yoshitaka

AU - Yonemaru, Makoto

AU - Nishio, Kazumi

AU - Shimada, Naoto

AU - Kawada, Ichiro

AU - Naoki, Katsuhiko

AU - Tasaka, Sadatomo

AU - Nishimura, Tomoyasu

AU - Ishizaka, Akitoshi

PY - 2007/11

Y1 - 2007/11

N2 - [Objective]: This study was conducted in patients of secondary infection with chronic respiratory disease in order to compare 5 day short-course therapies employing gatifloxacin(GFLX) and levofloxacin(LVFX). In addition to the shortening of treatment periods, we also investigated the economic efficiency of this medical treatment. [Materials and methods]: A total of 74 patients with secondary infection in chronic respiratory disease were enrolled and treated with the study drugs. The study was conducted between September, 2006 and April, 2007 at Keio University Hospital and its affiliated hospitals and clinics. This was a randomized study in which patients were randomly assigned to one of the following two treatment groups: GFLX group (200 mg twice daily for patients aged ≧ 65 years and 400 mg twice daily in patients aged < 65 years), LVFX group (400 mg twice daily). The duration of antibiotic therapy was 5 days. [Results]: 61 patients (GFLX group: 32, LVFX group: 29) were evaluated for the efficacy of the medications, 74 patients (GFLX group: 37, LVFX group: 37) were evaluated for side effects, and 63 patients (GFLX group: 30, LVFX group: 33) were evaluated for abnormal laboratory results from a total of 74 patients. Clinical efficacy was 90.6% (29/32) in the GFLX group and 89.7% (26/29) in the LVFX group. Side effects were observed in 2 cases in the GFLX group, and 2 abnormal laboratory results were observed (1 in the GFLX group and 1 in the LVFX group). These cases were all mild in nature. [Conclusion]: Conventional management recommends 7-14 days of antibiotic therapy for secondary infection in patients with chronic respiratory disease. However, the optimum duration of treatment is less clear. This study suggests that for secondary infection in chronic respiratory disease, 5 day short-course therapy employing antibiotics therapy can be clinically successful. In terms of the economic efficiency of this medical treatment, GFLX is superior to LVFX due to the lower cost of this drug. These results show that therapy involving a 5 day short-course using GFLX is of greater benefit than therapy involving the use of LVFX.

AB - [Objective]: This study was conducted in patients of secondary infection with chronic respiratory disease in order to compare 5 day short-course therapies employing gatifloxacin(GFLX) and levofloxacin(LVFX). In addition to the shortening of treatment periods, we also investigated the economic efficiency of this medical treatment. [Materials and methods]: A total of 74 patients with secondary infection in chronic respiratory disease were enrolled and treated with the study drugs. The study was conducted between September, 2006 and April, 2007 at Keio University Hospital and its affiliated hospitals and clinics. This was a randomized study in which patients were randomly assigned to one of the following two treatment groups: GFLX group (200 mg twice daily for patients aged ≧ 65 years and 400 mg twice daily in patients aged < 65 years), LVFX group (400 mg twice daily). The duration of antibiotic therapy was 5 days. [Results]: 61 patients (GFLX group: 32, LVFX group: 29) were evaluated for the efficacy of the medications, 74 patients (GFLX group: 37, LVFX group: 37) were evaluated for side effects, and 63 patients (GFLX group: 30, LVFX group: 33) were evaluated for abnormal laboratory results from a total of 74 patients. Clinical efficacy was 90.6% (29/32) in the GFLX group and 89.7% (26/29) in the LVFX group. Side effects were observed in 2 cases in the GFLX group, and 2 abnormal laboratory results were observed (1 in the GFLX group and 1 in the LVFX group). These cases were all mild in nature. [Conclusion]: Conventional management recommends 7-14 days of antibiotic therapy for secondary infection in patients with chronic respiratory disease. However, the optimum duration of treatment is less clear. This study suggests that for secondary infection in chronic respiratory disease, 5 day short-course therapy employing antibiotics therapy can be clinically successful. In terms of the economic efficiency of this medical treatment, GFLX is superior to LVFX due to the lower cost of this drug. These results show that therapy involving a 5 day short-course using GFLX is of greater benefit than therapy involving the use of LVFX.

KW - 5-day therapy

KW - Chronic respiratory disease

KW - Gatifloxacin

KW - Levofloxacin

KW - Secondary infection

UR - http://www.scopus.com/inward/record.url?scp=37349075257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349075257&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:37349075257

VL - 55

SP - 451

EP - 462

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 6

ER -